June 2023

Structural racism and inequity in global diabetes care; obesity & cancer risk; lawsuits against compounded GLP-1s; and, the end of BMI

Structural racism and inequity in global diabetes care; obesity & cancer risk; lawsuits against compounded GLP-1s; and, the end of BMI???

Hello all, I hope everyone is having a terrific weekend! We are quite excited here at twenty30 health, as we will be attending the annual conference of the American Society of Metabolic and Bariatric Surgery (ASMBS) in Las Vegas this week, in force; see more below. We look forward to connecting with colleagues and friends, old […]

Structural racism and inequity in global diabetes care; obesity & cancer risk; lawsuits against compounded GLP-1s; and, the end of BMI??? Read More »

Insurers “clamping down” on costly GLP-1s; BMI challenged; teens and obesity treatment; and skyrocketing Type 2 diabetes in India.

Hope everyone is quite well this week. For those dads out there, warm wishes for a very happy Father’s Day! And I’d also like to note, with deep respect, that tomorrow is Junteenth and a holiday for twenty30 health, as we commemorate the emancipation of enslaved Black Americans on what many view as America’s second Independence

Insurers “clamping down” on costly GLP-1s; BMI challenged; teens and obesity treatment; and skyrocketing Type 2 diabetes in India. Read More »

Obesity meds and affordability; Ozempic covered by NHS in the UK and becomes a frenzy in China; GLP-1s, addiction and desire; and pets with obesity!

Obesity meds and affordability; Ozempic covered by NHS in the UK and becomes a frenzy in China; GLP-1s, addiction and desire; and pets with obesity!

AT A GLANCE Ozempic to be covered by the UK National Health Service under a £40 million two-year pilot, with commentary from Prime Minister Rishi Sunak. CNN reports on the Ozempic frenzy sweeps China, with local firms developing generic versions of semaglutide. GLP-1 drugs, addiction and desire are covered in The New York Times. It’s not just humans; 59% of dogs and 61% of cats

Obesity meds and affordability; Ozempic covered by NHS in the UK and becomes a frenzy in China; GLP-1s, addiction and desire; and pets with obesity! Read More »

A bumper two-week review, with Noom on GLP-1s, Chrissy Farr and Rock Health review metabolic health, bariatric surgery in teens, and more.

A bumper two-week review, with Noom on GLP-1s, Chrissy Farr and Rock Health review metabolic health, bariatric surgery in teens, and more.

AT A GLANCE Noom, a behavior change platform, announces a new program — “Noom Med” — to incorporate anti-obesity medications. Restriction of access to Ozempic and Wegovy, by ‘…employers’ health plans [who] won’t pay for them…’, is covered by The Wall Street Journal. Rock Health focuses on whole person view of obesity care, to comprise a serviceable addressable market of almost $13B. Sima Sistani,

A bumper two-week review, with Noom on GLP-1s, Chrissy Farr and Rock Health review metabolic health, bariatric surgery in teens, and more. Read More »

Scroll to Top
Skip to content